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In this issue of Ceil, we take the unusual step of publishing 
two articles each of which reports the identification of a 
different gene in the appropriate chromosomal region as- 
sociated with the human disease of spinal muscular atro- 
phy (SMA). Each paper individually meets the standard 
for publication in providing adequate evidence to identify 
systematic changes in the gene in patients with the dis- 
ease but not in normal people, but the two groups have 
identified unrelated genes, called SMN and NAIP. 
SMA is a relatively common recessive autosomal dis- 
ease, affecting - 1 in 6000 births, and is one of the most 
common genetic causes of death in childhood. Three clini- 
cal types of the disease (I, II, and III) are distinguished by 
the (decreasing) severity of the symptoms. The common 
cause is depletion of motor neurons in the spinal cord, 
resulting in muscular atrophy with consequent paralysis of 
limb and trunk. All three types of SMA map to chromosome 
region 5q11.2-q13.3, and several research groups have 
been engaged for some years in constructing molecular 
maps of this region in order to identify the causal locus. 
The search for SMA has been complicated by the insta- 
bility of this chromosomal region; it has many repetitive 
sequence elements that often cause instability in cloned 
sequences. It has several classes of expressed pseu- 
dogenes, which have an interrupted organization and 
generate transcripts that are spliced to give mRNA-like 
molecules that do not give functional products. This com- 
plicates attempts to identify the gene(s) for SMA, because 
lOOkb 
probes for coding regions react with the pseudogenes and 
their transcripts as well as with the sequences of any au- 
thentic gene. 
SMN Lies in a Large Inverted Duplication 
The report from Lefebvre et al. (1995) utilizes CEPH YAC 
libraries prepared from a single human donor. The YACs 
were mapped by PFGE of restriction fragments, and the 
locations of polymorphic microsatellite markers on these 
YACs were determined by PCR screening. The map 
shown in Figure 1 has an inverted duplication of -500  
kb. The two repeats are distinguished by the different sizes 
of restriction fragments obtained with Hindlll; the centro- 
meric repeat has a fragments of 12 kb and 3.7 kb, while 
the telomeric repeat has fragments of 11 kb and 3.7 kb. 
Both sets of fragments are present in normal individuals 
and also in a monochromosomal hybrid cell line, sug- 
gesting that they represent a bona fide duplication and 
not allelic polymorphism. Confirming the instability of this 
chromosomal region, PFGE analysis of large restriction 
fragments shows extensive polymorphism in the normal 
as well as the patient population. 
Patients with type I or type II SMA (and more rarely with 
type III SMA) have deletions in the telomeric repeating 
unit that extend from the microsatellite marker C272 to 
the 11 kb He3 fragment. Screening of fetal brain cDNAs 
identified a clone (BCD541) that corresponds to a widely 
expressed transcription unit of 1.7 kb. This clone identifies 
a gene, called SMN, that has 8 exons extending over - 20 
kb. There is a copy of the gene in both the telomeric and 
centromeric repeating units, and the copies are virtually 
identical; 5 base substitutions have been identified, 2 of 
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Figure 1. A YAC contig shows an inverted duplication of the region. Sites for restriction markers are shown above the map; the locations of 
polymorphic microsatellite markers are shown below the map. He3 identifies the locations of the restriction fragments obtained with Hindltl. The 
copy of the SMA gene associated with disease is identified as SMNSMA; the other is shown as SMN °°py. These are identified by the markers ~BCD541 
and CBCD541 on the map of Lefebvre et al., respectively. 
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which lie in exons 7 and 8, and none of which affects the 
coding of the protein product. SSCP analysis of the regions 
containing the sites that differ therefore allows the centro- 
meric and telomeric copies to be distinguished in exons 
7 and 8. 
When 229 patients were screened for the presence of 
exons 7 and 8, most (213) lacked the telomeric copy of 
both exons, and 13 lacked the telomeric copy of exon 7 
but retained exon 8. This indicates that the vast majority 
of patients have a deletion of at least the 3' end of the 
gene (and possibly of the entire gene), and a small number 
have a truncation of the gene from the 5' end. This sug- 
gests that the right chromosomal region has been identi- 
fied, but does not equate the disease with the gene, since 
the deletion is not demonstrated to be confined exclusively 
within it. However, the remaining 3 patients satisfy this 
standard. Each has a different mutation. One has a dele- 
tion at the splice acceptor site of intron 6, and another 
has a deletion at the splice donor site of intron 7; both of 
these patients have only one (mutant) allele, the other 
allele being entirely absent. Their inheritance of these al- 
leles can be traced from heterozygous parents. It is fortu- 
nate (and perhaps surprising) that the individual mutations 
occurred within the regions that can be distinguished be- 
tween the telomeric and centromeric copies of the gene. 
The third patient has two coding sequences for exon 6, 
one carrying a mutation that converts tyrosine to cysteine, 
leading to the surmise that the mutation lies in the telo- 
meric copy. None of the mutations found in these three 
patients occurs in the normal population, suggesting that 
they are causal for the disease, and not the result of a 
polymorphism. 
NAIP Has Many Deleted Pseudogenes 
A similar approach in covering the region has been fol- 
lowed by Roy et al. (1995), who first developed a YAC 
contig that uses YACs derived from three libraries, and 
then moved to a PAC (P1 artificial chromosome) contig. 
They have mapped tandem repeats mostly based on 
highly polymorphic CA, tracts; their map is shown in Figure 
2. They also screened a fetal brain cDNA library with a 
PAC that contained the polymorphic markers showing the 
greatest association with the disease, and identified a 
gene, called NAIP, of at least 16 exons dispersed over 
60 kb. When blots of BamHI-digested genomic DNA are 
probed with exons 2-10 of NAIP, three bands are found. 
A band of 14.5 kb represents two equally sized fragments 
that represent he central 29 kb of the gene. A band of 
23 kb results from a 6 kb deletion that removes exons 
5-6 and the central BamH1 site. A band of 9.6 kb repre- 
sents a gene that has lost its 5' end upstream of exon 7. 
The 9.6 and 23 kb bands occur at variable dosage in the 
general population, suggesting that they represent pseu- 
dogenes that vary in number between individuals. In fact, 
a cDNA library from normal fetal brain tissue contains a 
large number of deleted variants, suggesting that he 
pseudogenes are transcribed. 
Probing genomic DNA for exons 5-6 shows that all nor- 
mal people display a 9.4 kb Ec~)R1 band representing the 
intact gene. 45% of SMA type I individuals and 18% of 
SMA type II or III individuals have a homozygous deletion 
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Figure 2. A PAC contig for the region associated with SMA has two 
copies of the NAIP gene; ~NAIP is a deleted copy, and NAIP is a copy 
that has markers associated with the disease. These are shown as 
*NAIP and NAIP, respectively, on the map of Roy et al. 
of these exons, implying an association of this region with 
the disease. In one pedigree, parents who displayed all 
three BamH1 bands had normal children, all of whom re- 
tained a 14.5 kb band, and had children with the disease, 
all of whom lacked the 14.5 kb band. Thus inheritance in 
homozygous tate of the deleted gene shows the expected 
correlation with the disease. However, a general examina- 
tion of the genotypes of parents whose children showed 
type I SMA identified three cases inwhich there appeared 
to be homozygous loss of exons 5-6 without phenotypic 
consequence, casting some doubt on whether this event 
alone is sufficient o cause the disease. This requires the 
introduction of arguments for an effect of penetrance, or 
involvement of additional oci. 
The correlation between NAIP and SMA was taken fur- 
ther by examining RNA from patients and normal people. 
Using primers for sequences in exon 10 or exon 13, cDNAs 
of the expected sizes could be amplified from all normal 
samples. In most cases, material could not be amplified 
from patients, suggesting a deficiency of expression of 
NAIP. In the exceptional cases in which cDNA was ob- 
tained from patients, sequencing of the products showed 
aberrations in every case. None of these changes could 
be detected in normal people. However, given the pres- 
ence of multiple pseudogenes, this does not necessarily 
imply that he NAIP gene carried the observed mutations 
in each patient; it could instead be the case that the NAIP 
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Figure 3. Various alignments of the two maps are possible, depending on which copies are taken to be equivalent. The copies directly associated 
with disease on each map are highlighted in black; others are named in grey. The two copies of SMN on the map of Lefebvre et al. are distinguished 
as SMN sw' and SMN~°PY; the two copies of NAIP are not distinguished. The two copies of NAIP on the map of Roy et al. are distinguished as 
~NAIP and NAIP; the two copies of SMN are not distinguished. 
gene has been deleted, and the amplification products 
represent expression of pseudogenes, which were not de- 
tected in normal samples because they represented a 
small proportion of transcripts relative to the wild-type 
gene. It is therefore clear that deletion of NAIP is associ- 
ated with the disease, but there is not yet a hereditary or 
sporadic demonstration of a change that can be shown 
to be confined only to the gene itself. 
Another cDNA that detects deletions in SMA type I pa- 
tients has been identified by Thompson et al. (1995). Origi- 
nally identified by an exon amplification technique, clone 
XS2G3 detects nonallelic Hindlll fragments of 17, 12, and 
4 kb. The 12 kb fragment is homozygously deleted in 17/ 
29 type I SMA patients, in only 1 type II patient, and not 
in type III patients; however, it is also absent from 2/235 
unaffected people, both carriers. This again suggests that 
type I SMA is caused by larger changes than type II or 
type Ill, but it remains to be seen whether XS2G3 identifies 
sequences in the causal gene. XS2G3 detects RNAs of 
various sizes. The exon that was amplified is part of a 3' 
UTR, and has the curious feature that it is complementary 
to part of exon 6 of NAIP. This reinforces the view of this 
region as highly variable. 
The presence of many pseudogenes in the SMA region 
itself poses a problem for validating any particular gene 
as a bona fide functional locus. Many of the pseudogenes 
are expressed at higher levels in brain than in other tissues 
(Bruno et al., 1994). (The number and variety of expressed 
pseudogenes brings to mind the old data that the complex- 
ity of RNA expressed in the brain is an order of magnitude 
greater than other tissues.) These pseudogenes may have 
exons containing interesting combinations of protein mo- 
tifs. How is one to tell whether any particular combination 
of exons found in the genome, and corresponding to vari- 
ous RNA products, represents a functional ocus? Some 
conviction is lent by characterizing the individual exons, 
but a decisive demonstration may require the cloning of 
a cDNA that actually represents an RNA in which all of 
the exons are juxtaposed, and can generate a functional 
protein product. 
Reconciling the Two Maps 
There seems no doubt that the region containing SMN 
and NAIP carries the mutations that cause SMA. Strong 
linkage disequilibrium with the SMA phenotype was found 
for markers within both genes (this means that in popula- 
tions the marker is tightly linked to the disease; it is an 
equivalent measure to assessing linkage as the result of 
a genetic cross). The genes in fact are adjacent (or to be 
more precise, certain copies of each gene are adjacent). 
Deletions that affect these genes are very strongly associ- 
ated with the disease, it is unlikely that the disease is 
caused by mutations that lie outside the - 500 kb region 
that contains the adjacent SMN and NAIP genes, although 
one would like to see a transcript map to determine what 
other genes lie in this region; and there remains the possi- 
bility that other genes in the immediate vicinity contribute 
to the disease. 
One urgent priority is to reconcile the maps obtained 
by the two groups. However, this region of the genome 
is highly polymorphic, and is replete with duplications and 
deletions. Only a few markers are common to both groups, 
but because of the repeated copies, it is difficult o make 
direct comparisons (note the locations of the markers 
CMS, C161/CATT1, and C272 on the maps of Figures 1 
and 2). Each group has identified regions corresponding to 
the gene identified by the other group, but has not directly 
shown which of these regions corresponds to the copy 
implicated in disease. 
Although both groups show two copies of each gene, 
these do not correspond directly, and the region character- 
ized in detail by Roy et al. appears to correspond to one 
of the inverted repeating units identified by Lefebvre et 
al. Thus one of the two copies of SMN identified by Roy 
et al. may correspond to one of the copies of SMN identi- 
fied by Lefebvre et al., but the second copy in each case 
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is probably not homologous, because the two copies are 
separated by -350 kb on the map of Roy et al, but -600  
kb on the map of Lefebvre et al. Similarly, it is not obvious 
which of the NAIP genes identified by Lefebvre et al. cor- 
responds to the NAIP gene of Roy et al. 
Thus it is difficult o know whether corresponding copies 
of the gene are being compared between the two maps. 
Of the several possibilities for reconciling the maps, each 
has its own problems. Suppose first of all that the copies 
identified with disease must lie at the same location. This 
would give the alignment of Figure 3A, but this places the 
SMN and NAIP genes in opposite orientation with regards 
to the centromere. If we conserve the orientation in which 
SMN is centromeric to NAIP, there are two possibilities. 
Figure 3B shows that the map of Roy et al. could be aligned 
with the centromeric repeating unit of Lefebvre et al. The 
problem here is that disease is now associated with the 
centromeric repeat for Roy et al. and with the telomeric 
repeat for Lefebvre et al. Figure 3C shows an alignment 
in which the other copy of SMN of Roy et al. is aligned 
with the disease copy of Lefebvre et al., which would mean 
that the SMN and NAIP loci associated with disease would 
be separated by one of the NAIP pseudogenes, posing a 
problem with the linkage disequilibrium mapping. 
We need to know whether the inverted duplication is 
general in the population (as suggested by the results of 
Lefebvre et al.) If it is, one of the copies of NAIP shown 
on the map of Figure 1 must lack exons 5-6, since Roy 
et al. show that there is only one NAIP locus with these 
exons. In fact, there appear to be deletions in the distal 
end of the telomeric repeating unit that could well include 
NAIP. If the inverted duplication is not common in the pop- 
ulation, we need to explain its occurrence in the library of 
Lefebvre et al., and to determine its relationship to the 
cause of disease. Certainly the map would be much sim- 
pler to analyze if there were only one repeating unit. Most 
contigs for markers linked to SMA phenotype appear to 
identify a region that corresponds to only a single (nondu- 
plicated) unit, but on the other hand, it is clear that duplica- 
tions and deletions are frequent (Carpten et al., 1994; 
Francis et al., 1993; Kleyn et al., 1993). 
Criteria for Assigning a Gene to the Disease 
The nature of the sequence of a gene does not necessarily 
provide information about its involvement in a disease. 
SMN codes for a small protein (294 amino acids) with no 
relations in the data base. NAIP codes for a large protein 
(1232 amino acids) and has a domain that shows homol- 
ogy with the baculoviral inhibitor of apoptosis. Loss of anti- 
apoptotic function would be consistent with the phenotype 
of swelling and lysis of motor neurons that typifies SMA. 
The expression pattern offers no help, because both 
genes are quite broadly expressed. No sequence relation- 
ship between the genes is evident. 
If the disease is associated with this confined region, 
how are we to distinguish whether it is caused by one of 
the genes (in which case the mutations in the other must 
be adventitious) or whether both are involved? The usual 
assumption in seeking the genetic cause for a disease 
that behaves as a Mendelian trait and maps to a defined 
chromosomal region is that a single gene will be responsi- 
ble. The standard for proving the case is taken to be the 
presence in patients but not in normal people of changes 
that are confined to that gene alone (that is, comprising 
internal deletions or point mutations). 
Lefebvre et al. have met this standard, but there is one 
feature that causes disquiet: the second (nonallelic) copy 
of the gene apparently has no inactivating mutations. That 
copy has a pattern of alternative splicing that generates 
transcripts lacking exon 7, but it also generates full-length 
transcripts, which presumably are functional. A reason- 
able expectation in this situation is that the nonallelic 
genes should be redundant and that mutation in either 
should not cause disease. If reduction of dosage were 
responsible for the disease, there would be no reason for 
the loss in patients to be confined to one copy rather than 
the other. However, 10% of normal people lack the centro- 
meric copy of SMN, implying that its deletion has no phe- 
notypic effect, and that there may be a functional differ- 
ence between the two copies of the gene. 
Roy et al. have the advantage of finding only a single 
functional ocus for NAIP, and they show strong associa- 
tion between deletion of that locus and the disease. The 
sequence of the gene offers a connection with the disease 
phenotype. However, it remains possible that all the muta- 
tions seen in patients extend beyond the gene into neigh- 
boring territory. Because of the existence of the pseu- 
dogenes, it is difficult o determine with individual exonic 
probes whether patients who (for example) have lost exons 
5-6 have done so as the result of internal deletion or have 
lost the entire NAIP locus. 
The existence of multiple pseudogenes for NAIP that 
have large deletions or truncations uggests that unequal 
crossing over between nonallelic copies could be one of 
the causes of instability in this region. Any such event 
would delete material between the sites of recombination, 
making it plausible that more than one gene may be af- 
fected, so that most of the observed deletions are not infor- 
mative. Clearly it becomes important o map the ends of 
the deletions in order to determine whether only one or 
more genes are lost, and whether there is a common de- 
nominator that relates to loss of SMN, NAIP, or other genes 
in the various types of SMA. 
As a note of caution, there is a precedent for the occur- 
rence of mutations that map to the right region in patients, 
but do not in fact identify the causal locus: the gene MCC 
is located in the chromosomal region associated with APC 
(adenomatous polyposis coil) and was identified as a can- 
didate for the cause of the disease on the basis of accumu- 
lation of mutations in tumors in sporadic cases (Kinzler et 
al., 1991). However, it turns out that the authentic APC 
gene lies 150 kb away, as identified by the occurrence of 
germline mutations in familial cases (Joslyn et al., 1991; 
Nishisho et al., 1991). Of course, the misleading mutations 
occurred in somatic tissue, and.there is so far no compara- 
ble case with germline mutations. 
Is it possible that both genes are associated with the 
disease? It is extremely rare in higher eucaryotes to find 
unrelated neighboring genes that code for proteins that 
function in the same pathway. One case is the example 
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of RAG1 and RAG2, both of which are needed for recombi- 
nation of immunoglobulin genes (Oettinger et al., 1990); 
deletion of either of the adjacent genes has the same effect 
on the phenotype. Some features of SMA could be inter- 
preted in terms of such a model. The varying types of the 
disease could be interpreted in terms of different causal 
loci or in terms of mutations of varying severity in a single 
locus. The latter explanation became favored as the result 
of demonstrations that different ypes of the disease map 
to the same chromosomal locus (Melki et al., 1990). How- 
ever, this would not distinguish the involvement of one 
locus from a role for multiple but adjacent loci. Almost all 
patients of SMA types I and II display deletions in SMN; 
patients with type III SMA do not have gross deletions, 
but have (presumably nonallelic) copies of the cBCD541 
sequence, which Lefebvre et al. propose could be ex- 
plained by a gene conversion of the telomeric gene to the 
sequence of the centromeric gene. In terms of large scale 
changes, deletion of NAIP is less common in type II and 
Ill than in type I SMA. 
These possibilities make it difficult o establish the stan- 
dard for proof. There have been cases in which the conven- 
tional criteria could not apply, most notably that of Char- 
cot-Marie-Tooth disease, which results from duplication 
of a locus (Lupski et al., 1991), it therefore being impossi- 
bie to demand a demonstration of internal mutations. The 
standard would also need to be different if mutations in 
either of two genes could cause disease, or if mutations 
in two genes were both necessary for disease. In the first 
case, the problem arises when there is no evident genetic 
heterogeneity and the two genes are in close proximity, 
because either gene individually should apparently be ex- 
cluded by patients that lack mutations in it. In the second 
case, all patients should have long deletions or multiple 
independent mutations. The next step to resolve the situa- 
tion with regards to SMA is to reconcile the two maps and 
to determine whether there is a systematic association of 
only one or both genes with the disease. In the long term, 
it may be necessary to move to a mouse model, by disrupting 
the appropriate homologs in isogenic backgrounds, to 
prove cause and effect. At all events, SMA promises to 
be one of the most interesting traits to characterize at the 
molecular level. 
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